News | July 29, 2007

FDA Nanotechnology Report Outlines Scientific, Regulatory Challenges

July 30, 2007 — The FDA's Nanotechnology Task Force released a report that recommends the agency consider developing guidance and taking other steps to address the benefits and risks of drugs and medical devices using nanotechnology.

"Nanotechnology holds enormous potential for use in a vast array of products," said Commissioner of Food and Drugs Andrew von Eschenbach, M.D., who endorsed the Task Force Report and its recommendations on July 23, 2007. "Recognizing the emerging nature of this technology and its potential for rapid development, this report fosters the continued development of innovative, safe and effective FDA-regulated products that use nanotechnology materials."

Scientists and researchers increasingly are working in the nanoscale, creating and using materials and devices at the level of molecules and atoms-1/100,000th the width of a human hair.

The FDA's Task Force Report on Nanotechnology addresses regulatory and scientific issues and recommends FDA consider development of nanotechnology-associated guidance for manufacturers and researchers. The Task Force was initiated by Commissioner von Eschenbach in 2006.

The Task Force reports that nanoscale materials potentially could be used in most product types regulated by FDA and that those materials present challenges similar to those posed by products using other emerging technologies. The challenges, however, may be complicated by the fact that properties relevant to product safety and effectiveness may change as size varies within the nanoscale.

The report also says that the emerging and uncertain nature of nanotechnology and the potentially rapid development of applications for FDA-regulated products highlight the need for ensuring transparent, consistent, and predictable regulatory pathways.

Anticipating the potential for rapid development in the field, the report recommends consideration of agency guidance that would clarify, for example, what information to give FDA about products, and also when the use of nanoscale materials may change the regulatory status of particular products. As with other FDA guidance, draft guidance documents would be made available for public comment prior to being finalized.

In addition, the report says the FDA should work to assess data needs to better regulate nanotechnology products, including biological effects and interactions of nanoscale materials. The agency also should develop in-house expertise and ensure consideration of relevant new information on nanotechnology as it becomes available, according to the report. FDA should evaluate the adequacy of current testing approaches to assess safety, effectiveness and quality of nanoscale materials.

FDA and 22 other federal agencies are part of the National Nanotechnology Initiative, a federal research and development program established to coordinate the multi-agency efforts in nanoscale science, engineering, and technology.

For more information: www.nano.gov and www.fda.gov

Related Content

more healthcare providers and patients are choosing options such as Gamma Knife stereotactic radiosurgery
News | Radiation Therapy | July 31, 2017
Each year, up to 650,000 people who were previously diagnosed with various forms of cancer will develop brain...
Surgery and High-Dose SBRT Radiation Can Be Combined to Treat Kidney Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | July 05, 2017
A new study from Roswell Park Cancer Institute reporting the findings of the first clinical trial to evaluate the...
ASTRO Issues Guideline for Stereotactic Radiation Use in Early-Stage Lung Cancer
Feature | Lung Cancer | June 23, 2017
The American Society for Radiation Oncology (ASTRO) recently issued a new clinical guideline for the use of...
stereotactic body radiation therapy (SBRT)
News | Stereotactic Body Radiation Therapy (SBRT) | June 12, 2017
The American Society for Radiation Oncology (ASTRO) issued a new clinical guideline for the use of stereotactic body...
Stereotactic Radiation Highly Effective for Kidney Cancer
News | Stereotactic Body Radiation Therapy (SBRT) | May 03, 2017
Kidney cancer patients may soon have an alternative to traditional treatments, according to new research at UT...
SBRT, stereotactic body radiation therapy, early-stage lung cancer, patients 80 and older, 2017 Multidisciplinary Thoracic Cancers Symposium, study
News | Stereotactic Body Radiation Therapy (SBRT) | March 20, 2017
Patients in their 80s and 90s who have early-stage lung cancer but cannot undergo an operation can be treated safely...
prostate cancer, partial gland, SBRT, clinical trial, UH Hospitals
News | Stereotactic Body Radiation Therapy (SBRT) | April 28, 2016
Physicians at University Hospitals Seidman Cancer Center (Cleveland) have started a clinical trial using a new form of...
prostate cancer, stereotactic body radiation therapy, SBRT, cure rate, UT Southwestern Study
News | Prostate Cancer | April 19, 2016
A five-year study shows that stereotactic body radiation therapy (SBRT) offers a higher cure rate for prostate cancer...
Overlay Init